From scientific complexity to market execution.

The bottleneck in In Vivo CAR T may be delivery rather than the CAR itself. This article examines ERTLNP, T-cell activation, mTOR signaling, CMC implications, and the emerging 2026 clinical landscape.

Four ISSCR 2026 keynotes point to one conclusion: gene delivery is the real bottleneck in cell and gene therapy. What it means for CMC, CDMOs, and capital.

Executive Summary If you only have three minutes to read this article, I hope you'll remember these six things first. The real challenge of Gene Therapy is not just finding the therapeutic gene, but how to safely and effectively deliver the gene into the right cells. AAV (Adeno-associated virus) is one of the most mature in vivo gene delivery platforms currently available. Researchers remove most of the virus's genes, retaining only the structures needed for delivery, and the